KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Shares Outstanding (Diluted Average): 2009-2025

Historic Shares Outstanding (Diluted Average) for Biomarin Pharmaceutical (BMRN) over the last 9 years, with Sep 2025 value amounting to $196.9 million.

  • Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) fell 0.13% to $196.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $196.9 million, marking a year-over-year decrease of 0.13%. This contributed to the annual value of $196.7 million for FY2024, which is 2.67% up from last year.
  • Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) amounted to $196.9 million in Q3 2025, which was down 0.10% from $197.1 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) ranged from a high of $200.5 million in Q2 2024 and a low of $182.9 million during Q4 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $196.7 million (2024), whereas its average is $196.4 million.
  • Per our database at Business Quant, Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) decreased by 7.32% in 2021 and then increased by 5.71% in 2022.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Shares Outstanding (Diluted Average) stood at $182.9 million in 2021, then climbed by 3.34% to $189.0 million in 2022, then rose by 1.39% to $191.6 million in 2023, then climbed by 2.67% to $196.7 million in 2024, then fell by 0.13% to $196.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $196.9 million for Q3 2025, versus $197.1 million for Q2 2025 and $196.5 million for Q1 2025.